Faculty profile

Bryan Lo

Back to faculty

Assistant ProfessorPathology and Laboratory MedicineUniversity of Ottawa

Bryan Lo

Assistant Professor

Pathology and Laboratory Medicine

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
20 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Latest papers

Targeted transcriptome profiling of oral cavity squamous cell carcinoma and histologic grade-associated gene expression patterns.
Journal of clinical pathology · 2026
Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC.
Current oncology (Toronto, Ont.) · 2026

All 33 publications

33 publications.

Targeted transcriptome profiling of oral cavity squamous cell carcinoma and histologic grade-associated gene expression patterns.

Ruschkowski B, Lo B, Wasserman JK

Journal of clinical pathology2026

DOI: 10.1136/jcp-2025-210614 PMID: 42580881

Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification.

Keyhanian K, Gilks CB, Mathew EP, Mack T, Sekhon H, Lo B, Greenstreet P, Grondin K, McAlpine JN, Jamieson A

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2026

DOI: 10.1016/j.modpat.2026.101030 PMID: 42320759

The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC.

Phillips WJ, Leong R, Yeung B, Al Lawati A, Camidge DR, Lo B, Wheatley-Price P

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33080439 PMID: 42645345

Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer.

Watt CL, Lelievre R, Parsons GCS, Vergette C, Chirip V, Polskaia N, Lapenskie J, Lo B, Campbell P, Bankapur A, Palidwor G, Downar J

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33060363 PMID: 42346263

Primary Nodal Poroid Hidradenocarcinoma With YAP1::NUTM1 Fusion: Report of a Rare Case.

Hosseini N, Sbeanaty O, Phillips WJ, Lo B, Sehdev S, Brenn T

Journal of cutaneous pathology2026

DOI: 10.1111/cup.70188 PMID: 42543568

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Goss G, Ciuleanu T, Ramlau R, Renouf DJ, Chu Q, Kalinka E, Sawrycki P, Bramson J, Nelson BH, Crabbé R

Therapeutic Advances in Medical Oncology20251 citations

DOI: 10.1177/17588359251332154

Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management.

Bisson KR, Beharry A, Blais N, Carter MD, Cheema PK, Desmeules P, Garratt JG, Melosky B, Lo B, Snow S, Tessier-Cloutier B, Tio E, Yip S, Won JR, Sheffield BS

JTO clinical and research reports2025

DOI: 10.1016/j.jtocrr.2025.100837 PMID: 40567262

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.

Lapuk A, Furman BLS, Feijao P, Baran E, Brahmbhatt S, Chan B, Nip KM, Kense A, Murphy B, Miller R, Funari V, Parker A, McConechy MK, Kassam S, Awan AA, Lo B, Breadner D, Stein BD, Huntsman DG

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol33010018 PMID: 41590338

Dominant Negative PTEN Alterations in Endometrial Carcinoma Are Associated With Retained Immunohistochemical PTEN Expression.

Keyhanian K, Busca A, Howitt B, Hammer P, Kingsley L, Lo B

The American journal of surgical pathology2025Senior author

DOI: 10.1097/pas.0000000000002412 PMID: 40401766

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.

Phillips WJ, Marginean H, Alrehaili M, Abdelrahim AA, Asmis T, Vickers M, Yeung B, Lo B, Goodwin R

Cancer treatment and research communications2025

DOI: 10.1016/j.ctarc.2025.100896 PMID: 40147102

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Bryan Lo

Research

Latest papers

Targeted transcriptome profiling of oral cavity squamous cell carcinoma and histologic grade-associated gene expression patterns.

Coexistent Endometrial and Fallopian Tube Carcinoma: Molecular and Pathological Features for Risk Stratification.

The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC.

Evaluating the Use of Tumor Bank DNA to Validate Genetic Factors Impacting Opioid Response in Patients with Advanced Cancer.

Primary Nodal Poroid Hidradenocarcinoma With YAP1::NUTM1 Fusion: Report of a Rare Case.

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Novel Approach to Proficiency Testing Reveals Significant Variations in Biomarker Practice Leading to Critical Differences in Lung Cancer Management.

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.

Dominant Negative PTEN Alterations in Endometrial Carcinoma Are Associated With Retained Immunohistochemical PTEN Expression.

Real-world evaluation of treatment patterns and clinical outcomes in patients with BRAF-V600E metastatic colorectal cancer (mCRC) in Canada.

Frequent collaborators

Daria Grafodatskaya

Paul Wheatley-Price

Cynthia Hawkins

Marcio Gomes

Tracy Stockley

Michael Ong

Kednapa Thavorn

Kednapa Thavorn

Bekim Sadikovic

Michael Fung-Kee-Fung

Arun Seth

Jim Dimitroulakos

Yvonne Bombard

Ming-Sound Tsao

John Woulfe

Aaron Pollett

George Yousef

James Downar

Amy Jamieson

Glenwood Goss

Philippe Joubert

Farshad Nassiri

Jonathan Bramson

Bruce Burns

Rosalyn Juergens